Chemomab Therapeutics (CMMB) Net Income towards Common Stockholders (QoQ) (2018 - 2025)
Chemomab Therapeutics (CMMB) Net Income towards Common Stockholders (QoQ) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Chemomab Therapeutics | 729.63 Mn | 719.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 35,917,280.20% |
| Dec 31, 2024 | 10,827,698.45% |
| Sep 30, 2024 | -4.08% |
| Jun 30, 2024 | -6.13% |
| Mar 31, 2024 | 13.20% |
| Dec 31, 2023 | -18.47% |
| Sep 30, 2023 | -46.96% |
| Jun 30, 2023 | -9.29% |
| Mar 31, 2023 | 5.56% |
| Dec 31, 2022 | 2.13% |
| Sep 30, 2022 | 11.02% |
| Jun 30, 2022 | 242.59% |
| Mar 31, 2022 | -1.35% |
| Dec 31, 2021 | -69.68% |
| Sep 30, 2021 | -7.15% |
| Jun 30, 2021 | -62.56% |
| Mar 31, 2021 | 73.31% |
| Dec 31, 2020 | -160.68% |
| Sep 30, 2020 | -126.55% |
| Jun 30, 2020 | 36.22% |